A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)

ClinicalTrials.gov ID: NCT07540897

Public ClinicalTrials.gov record NCT07540897. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 5, 2026, 6:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 Study 304)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to measure decreases in daytime sleepiness, cataplexy (sudden loss of muscle tone), and disease symptoms in participants with NT1 when taking ALKS 2680 tablets compared with placebo tablets.

Study identification

NCT ID: NCT07540897
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Alkermes, Inc.; Industry
Enrollment: 150 participants

Conditions and interventions

Conditions

Narcolepsy Type 1

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 70 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 12, 2026
Primary completion: May 31, 2027
Completion: Jun 30, 2027
Last update posted: Sep 2, 2026

2026 – 2027

United States locations

U.S. sites: 14
U.S. states: 8
U.S. cities: 14

Facility	City	State	ZIP	Site status
Alkermes Investigational Site	Brandon	Florida	33511	Recruiting
Alkermes Investigational Site	Miami	Florida	33176	Recruiting
Alkermes Investigational Site	Winter Park	Florida	32789	Recruiting
Alkermes Investigational Site	Atlanta	Georgia	30328	Recruiting
Alkermes Investigational Site	Macon	Georgia	31210	Recruiting
Alkermes Investigational Site	Lansing	Michigan	48911	Recruiting
Alkermes Investigational Site	St Louis	Missouri	63123	Recruiting
Alkermes Investigational Site	Charlotte	North Carolina	28210	Recruiting
Alkermes Investigational Site	Cincinnati	Ohio	45245	Recruiting
Alkermes Investigational Site	Colombia	South Carolina	29201	Recruiting
Alkermes Investigational Site	Dallas	Texas	75251	Recruiting
Alkermes Investigational Site	Frisco	Texas	75033	Recruiting
Alkermes Investigational Site	San Antonio	Texas	78229	Recruiting
Alkermes Investigational Site	Sugar Land	Texas	77478	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07540897, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 2, 2026 · Synced Sep 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07540897 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →